Related Experiment Video
Updated: Jan 26, 2026

Generation of Induced-pluripotent Stem Cells Using Fibroblast-like Synoviocytes Isolated from Joints of Rheumatoid Arthritis Patients
Published on: October 16, 2016
Abatacept alleviates rheumatoid arthritis development by inhibiting migration of fibroblast-like synoviocytes via
1Department of Rheumatology, Yantaishan Hospital, Yantai, China. uilao9352@163.com.
Objective:
To investigate whether Abatacept could regulate the occurrence and progression of rheumatoid arthritis (RA) by mediating cell migration of fibroblast-like synoviocytes (FLS) via mitogen-activated protein kinase (MAPK) pathway.
Patients And Methods:
Levels of MMP1, MMP3 and MMP13 in RA-FLS treated with Abatacept or MAPK pathway inhibitor were detected by quantitative Real-time-polymerase chain reaction (qRT-PCR) and enzyme-linked immunosorbent assay (ELISA), respectively. The regulatory effect of Abatacept on MAPK pathway was detected by Western blot. Transwell assay was performed to access the role of Abatacept in regulating cell migration of RA-FLS.
Results:
Abatacept treatment remarkably downregulated levels of MMP1, MMP3 and MMP13 in FLS, which were confirmed by qRT-PCR and ELISA. Migratory ability of FLS was inhibited by Abatacept treatment. Western blot results suggested that Abatacept treatment downregulated MAPK pathway-related genes in FLS. The effects of Abatacept on MMPs expressions and cell migration were partially reversed by SB203580 treatment, the MAPK pathway inhibitor.
Conclusions:
Abatacept inhibits FLS migration and MMPs expressions via inhibiting MAPK pathway, thereby inhibiting RA development.
Insights
Abatacept inhibits rheumatoid arthritis (RA) progression by reducing fibroblast-like synoviocytes (FLS) migration and matrix metalloproteinase (MMP) expression through the mitogen-activated protein kinase (MAPK) pathway.
Area of Science:
- Immunology
- Cell Biology
- Rheumatology
Background:
- Rheumatoid arthritis (RA) is characterized by inflammation and joint destruction.
- Fibroblast-like synoviocytes (FLS) play a key role in RA pathogenesis by migrating and producing matrix metalloproteinases (MMPs).
- The mitogen-activated protein kinase (MAPK) pathway is implicated in regulating FLS activity.
Purpose of the Study:
- To investigate Abatacept's effect on FLS migration and MMP expression.
- To determine if Abatacept modulates the MAPK pathway in RA-FLS.
- To elucidate the mechanism by which Abatacept influences RA progression.
Main Methods:
- Quantitative Real-time-polymerase chain reaction (qRT-PCR) and ELISA were used to measure MMP1, MMP3, and MMP13 levels.
- Western blot analysis assessed MAPK pathway activation.
- Transwell assays evaluated FLS migratory capacity.
Main Results:
- Abatacept significantly downregulated MMP1, MMP3, and MMP13 expression in RA-FLS.
- Abatacept treatment inhibited FLS migration.
- Abatacept downregulated MAPK pathway-related genes, and this effect was partially reversed by a MAPK inhibitor.
Conclusions:
- Abatacept inhibits FLS migration and MMP expression by downregulating the MAPK pathway.
- These actions suggest Abatacept can mitigate RA development.
- Abatacept represents a potential therapeutic strategy for RA.
Related Concept Videos
Feedback Inhibition
MAPK Signaling Cascades
C4 Pathway and CAM
C4 Pathway
The C4 pathway is used by plants such as...
Introduction to Fibroblasts
Migration
Enzyme Inhibition

